A compound having a molecular weight of 3000 or less and a partial structure represented by Formula (X) is provided:

##STR00001##

In Formula (X), a ring W.sup.1 represents a ring structure having at least one double bond as a constituent element of the ring and having no aromaticity; and R.sup.3 represents a heterocyclic group, a halogen atom, a nitro group, a cyano group, a hydroxy group, a thiol group, a carboxy group, —SF.sub.5, —SF.sub.3, —SO.sub.3H, —SO.sub.2H, an aliphatic hydrocarbon group having 1 to 25 carbon atoms which may have a substituent, or an aromatic hydrocarbon group having 6 to 18 carbon atoms which may have a substituent.

The present disclosure is directed to methods for treating diseases for which cysteamine is indicated and compounds useful in such methods.

The present disclosure is directed to methods for treating diseases for which cysteamine is indicated and compounds useful in such methods.

Novel lipids, compositions, and methods of using the novel lipids and compositions are disclosed. Three-component lipid nanoparticle compositions comprising the novel lipids or other types of lipids, and methods of using the three-component lipid nanoparticle compositions are disclosed. Three-component lipid nanoparticle compositions contain a steroidal or structural lipid-containing component, a PEGylated lipid-containing component, a cationic or ionizable lipid-containing component, and are free of phospholipids. Pharmaceutical formulations including the three-component lipid nanoparticle compositions and further including therapeutic and/or prophylactics such as mRNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs.

Novel lipids, compositions, and methods of using the novel lipids and compositions are disclosed. Three-component lipid nanoparticle compositions comprising the novel lipids or other types of lipids, and methods of using the three-component lipid nanoparticle compositions are disclosed. Three-component lipid nanoparticle compositions contain a steroidal or structural lipid-containing component, a PEGylated lipid-containing component, a cationic or ionizable lipid-containing component, and are free of phospholipids. Pharmaceutical formulations including the three-component lipid nanoparticle compositions and further including therapeutic and/or prophylactics such as mRNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs.

The present invention discloses a hypocrellin derivative substituted both in a pen-position and in a 2-position by an amino, and a preparation method and use thereof. A general structural formula of the derivative is as represented by formulas I-a to I-d: ##STR00001## The hypocrellin derivative substituted both in a peri-position and in a 2-position by an amino prepared in the present invention has a maximum absorption wavelength of 600-650 nm and a molar extinction coefficient reaching about 20000-40000 M.sup.−1cm.sup.−1. Compared with unmodified hypocrellin or hypocrellin having only a 2-position modified, an absorption spectrum of the derivative is significantly red-shifted and the molar extinction coefficient is greatly improved, and the derivative can efficiently produce reactive oxygen species such as singlet oxygen in a photosensitive condition. In the same condition, the hypocrellin derivative substituted both in a pen-position and in a 2-position by an amino involved in the present invention, when used as a photosensitizer, has a stronger ability to photo-dynamically inactivate tumor cells than the first and second generation commercial photosensitizers.

The present invention discloses a hypocrellin derivative substituted both in a pen-position and in a 2-position by an amino, and a preparation method and use thereof. A general structural formula of the derivative is as represented by formulas I-a to I-d: ##STR00001## The hypocrellin derivative substituted both in a peri-position and in a 2-position by an amino prepared in the present invention has a maximum absorption wavelength of 600-650 nm and a molar extinction coefficient reaching about 20000-40000 M.sup.−1cm.sup.−1. Compared with unmodified hypocrellin or hypocrellin having only a 2-position modified, an absorption spectrum of the derivative is significantly red-shifted and the molar extinction coefficient is greatly improved, and the derivative can efficiently produce reactive oxygen species such as singlet oxygen in a photosensitive condition. In the same condition, the hypocrellin derivative substituted both in a pen-position and in a 2-position by an amino involved in the present invention, when used as a photosensitizer, has a stronger ability to photo-dynamically inactivate tumor cells than the first and second generation commercial photosensitizers.

Provided is a compound of Formula (I): ##STR00001## wherein the variable groups are defined herein.

Provided is a compound of Formula (I): ##STR00001## wherein the variable groups are defined herein.

The present invention discloses a hypocrellin derivative substituted both in a peri-position and in a 2-position by an amino, and a preparation method and use thereof. A general structural formula of the derivative is as represented by formulas I-a to I-d:

##STR00001##

The hypocrellin derivative substituted both in a peri-position and in a 2-position by an amino prepared in the present invention has a maximum absorption wavelength of 600-650 nm and a molar extinction coefficient reaching about 20000-40000 M.sup.−1cm.sup.−1. Compared with unmodified hypocrellin or hypocrellin having only a 2-position modified, an absorption spectrum of the derivative is significantly red-shifted and the molar extinction coefficient is greatly improved, and the derivative can efficiently produce reactive oxygen species such as singlet oxygen in a photosensitive condition. In the same condition, the hypocrellin derivative substituted both in a peri-position and in a 2-position by an amino involved in the present invention, when used as a photosensitizer, has a stronger ability to photo-dynamically inactivate tumor cells than the first and second generation commercial photosensitizers.